Background and aims:To investigate the association between serum IP-10 and HBsAg levels in chronic hepatitis B(CHB)patients previously treated with nucleot(s)ide analogs(NAs)followed by combined treatment with an NA a...Background and aims:To investigate the association between serum IP-10 and HBsAg levels in chronic hepatitis B(CHB)patients previously treated with nucleot(s)ide analogs(NAs)followed by combined treatment with an NA and pegylated interferon alpha(PEG-IFNα).Methods:Ninety-nine patients with serum levels of HBsAg<3000 IU/mL and HBV DNA<20 IU/mL who received prior NA treatment were enrolled.Participants were administered either NA monotherapy(NA group)or combination therapy with PEG-IFNα(Add-on group).Laboratory indicators and IP-10 levels were assessed in serial peripheral blood samples collected at 12-and 24-week intervals.The outcome of this study was a loss or>1 log10 IU/mL decline in serum HBsAg.Results:After 48 weeks of antiviral therapy,none of the 27 NA group patients and 15 of the 72 Add-on group patients achieved HBsAg loss.Baseline serum HBsAg and IP-10 levels were equivalent across both groups.The combination treatment led to a decrease in serum HBsAg levels and an early increase in IP-10 levels.Furthermore,a moderate increase in IP-10 levels at weeks 12 or 24 was correlated with loss and decline of HBsAg in the Add-on group.Receiver operating characteristic curve and regression analyses demonstrated that a moderate increase in serum IP-10 levels at weeks 12 or 24 was predictive of HBsAg loss and decline in the Add-on group(p<0.05).Conclusion:An early and moderate increase in the serum IP-10 level was correlated with responses to PEG-IFNαamong patients with CHB treated with NAs.展开更多
基金supported by the National Key Research and Devel-opment Program of China(Grant No.2023YFC2308103)Capital Clinical Diagnosis and Treatment Technology Research and Transformation Application Project(Z201100005520046)the Capital Health Research and Development of Special(2020-1-2181,2022-1-2172).
文摘Background and aims:To investigate the association between serum IP-10 and HBsAg levels in chronic hepatitis B(CHB)patients previously treated with nucleot(s)ide analogs(NAs)followed by combined treatment with an NA and pegylated interferon alpha(PEG-IFNα).Methods:Ninety-nine patients with serum levels of HBsAg<3000 IU/mL and HBV DNA<20 IU/mL who received prior NA treatment were enrolled.Participants were administered either NA monotherapy(NA group)or combination therapy with PEG-IFNα(Add-on group).Laboratory indicators and IP-10 levels were assessed in serial peripheral blood samples collected at 12-and 24-week intervals.The outcome of this study was a loss or>1 log10 IU/mL decline in serum HBsAg.Results:After 48 weeks of antiviral therapy,none of the 27 NA group patients and 15 of the 72 Add-on group patients achieved HBsAg loss.Baseline serum HBsAg and IP-10 levels were equivalent across both groups.The combination treatment led to a decrease in serum HBsAg levels and an early increase in IP-10 levels.Furthermore,a moderate increase in IP-10 levels at weeks 12 or 24 was correlated with loss and decline of HBsAg in the Add-on group.Receiver operating characteristic curve and regression analyses demonstrated that a moderate increase in serum IP-10 levels at weeks 12 or 24 was predictive of HBsAg loss and decline in the Add-on group(p<0.05).Conclusion:An early and moderate increase in the serum IP-10 level was correlated with responses to PEG-IFNαamong patients with CHB treated with NAs.
